Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023GlobeNewsWire • 07/07/23
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) TabletGlobeNewsWire • 06/28/23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific SessionsGlobeNewsWire • 06/24/23
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023GlobeNewsWire • 06/15/23
Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?Zacks Investment Research • 06/08/23
Esperion to Present New Key Science at the American Diabetes Association's 83rd Scientific Sessions 2023GlobeNewsWire • 06/08/23
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/25/23
Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)Benzinga • 03/29/23
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 03/22/23